Colchicine, an alkaloid compound belonging to Microtubule-Targeting Agents (MTAs), has gained interest for its anti-cancer activity. By interacting with tubulin, colchicine can block the formation of the mitotic spindle during mitosis, thereby arresting cell proliferation. The potential of this drug to block the growth of cancer cells is significant. However, colchicine has been associated with gastrointestinal side effects after oral administration, while intravenously, it has been shown to cause necrosis and even death. For this reason, new derivatives have been developed to improve the pharmacological performances of Colchicine. CCI-001 is a Colchicine derivative, which has demonstrated efficacy in vitro against different cancer cells at extremely low doses due to its high affinity to β-III tubulin.